Product Name :
Arzoxifene hydrochloride
Description:
Arzoxifene hydrocloride is a selective estrogen receptor modulator that is a potent estrogen antagonist in mammary and uterine tissue while acting as an estrogen agonist to maintain bone density and lower serum cholesterol.
CAS:
182133-27-3
Molecular Weight:
512.06
Formula:
C28H30ClNO4S
Chemical Name:
2-(4-methoxyphenyl)-3-{4-[2-(piperidin-1-yl)ethoxy]phenoxy}-1-benzothiophen-6-ol; chlorohydrogen
Smiles :
Cl.COC1C=CC(=CC=1)C1SC2=CC(O)=CC=C2C=1OC1C=CC(=CC=1)OCCN1CCCCC1
InChiKey:
NHSNLUIMAQQXGR-UHFFFAOYSA-N
InChi :
InChI=1S/C28H29NO4S.ClH/c1-31-22-8-5-20(6-9-22)28-27(25-14-7-21(30)19-26(25)34-28)33-24-12-10-23(11-13-24)32-18-17-29-15-3-2-4-16-29;/h5-14,19,30H,2-4,15-18H2,1H3;1H
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.{{Fosaprepitant dimeglumine} medchemexpress|{Fosaprepitant dimeglumine} Neurokinin Receptor|{Fosaprepitant dimeglumine} Technical Information|{Fosaprepitant dimeglumine} In Vivo|{Fosaprepitant dimeglumine} custom synthesis|{Fosaprepitant dimeglumine} Epigenetics}
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
Arzoxifene hydrocloride is a selective estrogen receptor modulator that is a potent estrogen antagonist in mammary and uterine tissue while acting as an estrogen agonist to maintain bone density and lower serum cholesterol.|Product information|CAS Number: 182133-27-3|Molecular Weight: 512.06|Formula: C28H30ClNO4S|Chemical Name: 2-(4-methoxyphenyl)-3-{4-[2-(piperidin-1-yl)ethoxy]phenoxy}-1-benzothiophen-6-ol; chlorohydrogen|Smiles: Cl.COC1C=CC(=CC=1)C1SC2=CC(O)=CC=C2C=1OC1C=CC(=CC=1)OCCN1CCCCC1|InChiKey: NHSNLUIMAQQXGR-UHFFFAOYSA-N|InChi: InChI=1S/C28H29NO4S.ClH/c1-31-22-8-5-20(6-9-22)28-27(25-14-7-21(30)19-26(25)34-28)33-24-12-10-23(11-13-24)32-18-17-29-15-3-2-4-16-29;/h5-14,19,30H,2-4,15-18H2,1H3;1H|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.{{Regorafenib} medchemexpress|{Regorafenib} Protein Tyrosine Kinase/RTK|{Regorafenib} Purity & Documentation|{Regorafenib} In stock|{Regorafenib} custom synthesis|{Regorafenib} Autophagy} |Shelf Life: ≥12 months if stored properly.PMID:23812309 |Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|Arzoxifene inhibits cell growth as effectively as the antiestrogen tamoxifen. Northern analysis reveals that arzoxifene exerts a statistically significant inhibition of pS2 and progesterone receptor B mRNA expression. Significant agonistic effect is observed on the antitrypsin mRNA expression. In contrast to estradiol and tamoxifen, arzoxifene does not upregulate cathepsin D mRNA and protein expression.|In Vivo:|Arzoxifene prevents the ovariectomy-induced increase in body weight and serum cholesterol levels of treated rats and lowers them to below sham levels in a dose dependent manner, with maximum efficacy similar to estrogen or raloxifene. Arzoxifene (LY353381.HCl) prevents loss of bone due to ovariectomy with an ED50 of about 0.01 mg/kg with maximal efficacy observed at 0.1-1 mg/kg/day. Arzoxifene (LY353381.HCl) antagonizes the estrogen-induced elevation in uterine weight down to vehicle-dosed control levels with ED50 of 0.03 mg/kg/day.|Products are for research use only. Not for human use.|